Compounds > elvucitabine
Page last updated: 2024-12-08

elvucitabine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID469717
CHEMBL ID38700
SCHEMBL ID1649928
MeSH IDM0260903

Synonyms (39)

Synonym
4-amino-5-fluoro-1-[(2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2(1h)-one
ach-126443
beta-l-fd4c
elvucitabine (usan/inn)
D03981
4-amino-5-fluoro-1-[(2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
.beta.-l-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine
.beta.-l-fd4c
elvucitabine
ach-126,443
l-f-d4c
l-d4fc
181785-84-2
l-fd4c
CHEMBL38700
4-amino-5-fluoro-1-((2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)pyrimidin-2(1h)-one
2(1h)-pyrimidinone, 4-amino-1-((2s,5r)-2,5-dihydro-5-(hydroxymethyl)-2-furanyl)-5-fluoro-
(-)fd4c
beta-l-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine
elvucitabine [usan:inn]
m09buf90c0 ,
ach 126,443
unii-m09buf90c0
ach 126443
2(1h)-pyrimidinone, 4-amino-1-(2,5-dihydro-5-(hydroxymethyl)-2-furanyl)-5-fluoro-, (2s-cis)-
elvucitabine [inn]
elvucitabine [usan]
bdbm50421604
SCHEMBL1649928
DTXSID20171185
AKOS030528240
J-011630
DB06236
b-l-fd4c
Q1334337
A14435
2(1h)-pyrimidinone, 4-amino-1-[(2s,5r)-2,5-dihydro-5-(hydroxymethyl)-2-furanyl]-5-fluoro-
CS-0066557
HY-117582

Research Excerpts

Effects

ExcerptReferenceRelevance
"Elvucitabine has a long half-life of approximately 100 h."( Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
Colucci, P; Ducharme, MP; Hoepelman, IM; Pottage, JC; Robison, H; Schürmann, D; Turgeon, J, 2009)		1.34
"Elvucitabine has a long half-life of approximately 100 h."( Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
Colucci, P; Ducharme, MP; Hoepelman, IM; Pottage, JC; Robison, H; Schürmann, D; Turgeon, J, 2009)		1.34

Pharmacokinetics

The pharmacokinetic behavior of elvucitabine was best described by a two-compartment linear model using two absorption rates and a first-order elimination rate. Elvuc itabine has a long half-life of approximately 100 h.

ExcerptReferenceRelevance
" The pharmacokinetic behavior of elvucitabine was best described by a two-compartment linear model using two absorption rates and a first-order elimination rate."( Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
Colucci, P; Ducharme, MP; Pottage, JC; Robison, H; Turgeon, J, 2009)		0.87

Bioavailability

The PK behavior of elvucitabine was best described by a two-compartment linear model using two absorption rates and an increase in the bioavailability after day 1. The decrease in elv cucabine bioavailability whenElvuc itabine is coadministered with ritonavir may be due to ritonovir's inhibiting influx gut transporters.

ExcerptReferenceRelevance
" The decrease in elvucitabine bioavailability when elvucitabine was coadministered with ritonavir may be due to ritonavir's inhibiting influx gut transporters."( Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
Colucci, P; Ducharme, MP; Pottage, JC; Robison, H; Turgeon, J, 2009)		0.92

Dosage Studied

ExcerptRelevanceReference
" Three different dosing regimens of elvucitabine were administered with lopinavir-ritonavir to 24 subjects with moderate levels of HIV."( Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
Colucci, P; Ducharme, MP; Hoepelman, IM; Pottage, JC; Robison, H; Schürmann, D; Turgeon, J, 2009)		0.89
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1EC50 (µMol)0.16000.00040.61539.7000AID200001; AID200002
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (121)

Assay IDTitleYearJournalArticle
AID47442Tested for cytotoxicity in human T-cell lymphoblastic leukemia cell line (CEM)1998Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1
Bis-S-acyl-2-thioethyl (SATE)-bearing monophosphate prodrug of beta-L-FD4C as potent anti-HBV agent.
AID544201AUC (0 to t) in human at 20 mg administered under fasting condition in presence of 300 mg of ritonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID544196Cmax in human at 20 mg administered under fasting condition2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID544206Central volume of distribution with respect to the bioavailability in human at 20 mg administered under fasting condition presence of 300 mg of ritonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID543743Time prior to start absorption at second absorption site in HIV1 infected human at 20 mg administered once every 48 hrs for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID543742Time prior to start absorption at first absorption site in HIV1 infected human at 20 mg administered once every 48 hrs for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID543508Cmax in HIV1 infected human at 20 mg after 24 hrs in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID544245Time prior to start absorption at second absorption site in human at 20 mg administered under fasting condition2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID544241Half life in human at 20 mg administered under fasting condition in presence of 300 mg of ritonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID79637In vitro inhibitory activity against proliferation of HBV viral cell1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Synthesis and comparative evaluation of two antiviral agents: beta-L-Fd4C and beta-D-Fd4C.
AID46570In vitro inhibitory activity against growth of HIV infected CEM cell line1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Synthesis and comparative evaluation of two antiviral agents: beta-L-Fd4C and beta-D-Fd4C.
AID543510Drug level in HIV1 infected human plasma at 20 mg after 24 hrs in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID543520Half life in HIV1 infected human at 10 mg qd for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID86372Tested for effective concentration against HBV treated with drug every 3 days for 9 days using human hepatoblastoma cell line HepG2 2.2.151998Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1
Bis-S-acyl-2-thioethyl (SATE)-bearing monophosphate prodrug of beta-L-FD4C as potent anti-HBV agent.
AID544194AUC (0 to t) in human at 20 mg administered under fasting condition2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID200002In vitro antiviral activity against HIV-1 Reverse transcriptase wild type2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
The role of 2',3'-unsaturation on the antiviral activity of anti-HIV nucleosides against 3TC-resistant mutant (M184V).
AID46362In vitro concentration required to inhibit 50% of CEM cell growth1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human
AID86396In vitro inhibitory activity against growth of HIV infected HepG2 cell line1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Synthesis and comparative evaluation of two antiviral agents: beta-L-Fd4C and beta-D-Fd4C.
AID3033Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human
AID544211Volume of distribution at steady state with respect to the bioavailability in human at 20 mg administered under fasting condition2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID543696Peripheral volume of distribution with respect to the bioavailability in HIV1 infected human at 20 mg administered once every 48 hrs for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID88981Compound concentration required to inhibit the viral cell proliferation by 50% against HIV; Range = 0.1-0.21998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological evaluation of a series of 2'-fluorinated-2',3'-dideoxy-2',3'-didehydro-(L)-nucleosides.
AID543507AUC (0 to 24 hrs) in HIV1 infected human at 20 mg after 24 hrs in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID544243Time prior to start absorption at first absorption site in human at 20 mg administered under fasting condition2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID543697Volume of distribution at steady state with respect to the bioavailability in HIV1 infected human at 20 mg administered once every 48 hrs for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID544210Peripheral volume of distribution with respect to the bioavailability in human at 20 mg administered under fasting condition presence of 300 mg of ritonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID155119The anti-HIV-1 activity was assayed in activated human peripheral blood mononuclear (PBM) cells, relative to RVT2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions.
AID543518Tmax in HIV1 infected human at 10 mg qd for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID39131In vitro inhibitory activity against growth of HIV infected B16 cell line1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Synthesis and comparative evaluation of two antiviral agents: beta-L-Fd4C and beta-D-Fd4C.
AID200001In vitro antiviral activity against HIV-1 Reverse transcriptase M184V mutant2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
The role of 2',3'-unsaturation on the antiviral activity of anti-HIV nucleosides against 3TC-resistant mutant (M184V).
AID544003Terminal half life in human at 20 mg administered under fasting condition2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID543745Absorption rate constant at second absorption site in HIV1 infected human at 20 mg administered once every 48 hrs for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hr2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID544200AUC (0 to 24 hrs) in human at 20 mg administered under fasting condition in presence of 300 mg of ritonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID543740Time prior to start absorption at first absorption site in HIV1 infected human at 20 mg after 24 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID543522Cmax in HIV1 infected human at 20 mg administered once every 48 hrs for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID544250Absorption rate constant at second absorption site in human at 20 mg administered under fasting condition presence of 300 mg of ritonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID104033Tested for cytotoxicity in murine lung carcinoma (M109); not cytotoxic at the highest concentration tested (70 uM)1998Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1
Bis-S-acyl-2-thioethyl (SATE)-bearing monophosphate prodrug of beta-L-FD4C as potent anti-HBV agent.
AID544246Time prior to start absorption at second absorption site in human at 20 mg administered under fasting condition presence of 300 mg of ritonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID543512Cmax in HIV1 infected human at 5 mg qd for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID544244Time prior to start absorption at first absorption site in human at 20 mg administered under fasting condition presence of 300 mg of ritonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID47311Cytotoxicity was determined in CEM cells, relative to RVT2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions.
AID543523Tmax in HIV1 infected human at 20 mg administered once every 48 hrs for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID544212Volume of distribution at steady state with respect to the bioavailability in human at 20 mg administered under fasting condition presence of 300 mg of ritonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID543768Distributional clearance with respect to the bioavailability in HIV1 infected human at 20 mg administered once every 48 hrs for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID197123In vitro inhibitory activity against growth of HIV infected Rat-1 cell line1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Synthesis and comparative evaluation of two antiviral agents: beta-L-Fd4C and beta-D-Fd4C.
AID86379Tested for the ability to inhibit HBV DNA synthesis at a concentration of 7 nM using human hepatoblastoma cell line HepG2 2.2.151998Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1
Bis-S-acyl-2-thioethyl (SATE)-bearing monophosphate prodrug of beta-L-FD4C as potent anti-HBV agent.
AID543747Apparent oral clearance in HIV1 infected human at 20 mg administered once every 48 hrs for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID543521AUC (0 to 24 hrs) in HIV1 infected human at 20 mg administered once every 48 hrs for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID106908Concentration required to inhibit 50% of HIV activity in MT-2 cells1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human
AID152794Tested in vitro for cytotoxicity against PBM cells1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.
AID86850Compound concentration required to inhibit the viral cell proliferation by 50% against HBV1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological evaluation of a series of 2'-fluorinated-2',3'-dideoxy-2',3'-didehydro-(L)-nucleosides.
AID544242Central volume of distribution with respect to the bioavailability in human at 20 mg administered under fasting condition2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID543746Oral bioavailability in HIV1 infected human at 20 mg after 24 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID543491AUC (0 to 24 hrs) in HIV1 infected human at 5 mg after 24 hrs presence of 400 mg of Lopinavir and 100 mg of itonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID543767Central volume of distribution with respect to the bioavailability in HIV1 infected human at 20 mg administered once every 48 hrs for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID543494Drug level in HIV1 infected human plasma at 5 mg after 24 hrs presence of 400 mg of Lopinavir and 100 mg of itonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID544207Distributional clearance with respect to the bioavailability in human at 20 mg administered under fasting condition2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID102615Tested in vitro for anticancer activity against MCF-7 cells1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.
AID543505Tmax in HIV1 infected human at 10 mg after 24 hrs presence of 400 mg of Lopinavir and 100 mg of itonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID100403Tested in vitro for anticancer activity against LNCaP cells1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.
AID543509Tmax in HIV1 infected human at 20 mg after 24 hrs in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID544193AUC (0 to 24 hrs) in human at 20 mg administered under fasting condition2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID47456Compound concentration required to inhibit cell growth by 50% against CEM cells1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological evaluation of a series of 2'-fluorinated-2',3'-dideoxy-2',3'-didehydro-(L)-nucleosides.
AID544248Absorption rate constant at first absorption site in human at 20 mg administered under fasting condition presence of 300 mg of ritonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID543493Tmax in HIV1 infected human at 5 mg after 24 hrs presence of 400 mg of Lopinavir and 100 mg of itonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID544247Absorption rate constant at first absorption site in human at 20 mg administered under fasting condition2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID543744Absorption rate constant at first absorption site in HIV1 infected human at 20 mg administered once every 48 hrs for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID543517Cmax in HIV1 infected human at 10 mg qd for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID86381Tested for the ability to inhibit HBV replication at a concentration of 40 nM using human hepatoblastoma cell line HepG2 2.2.151998Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1
Bis-S-acyl-2-thioethyl (SATE)-bearing monophosphate prodrug of beta-L-FD4C as potent anti-HBV agent.
AID217732Cytotoxicity was determined in Vero cells, relative to RVT2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions.
AID200144Ratio for inhibition of HIV-1 RT to that of type and HIV-1 RT M184V mutant was determined2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
The role of 2',3'-unsaturation on the antiviral activity of anti-HIV nucleosides against 3TC-resistant mutant (M184V).
AID543504Cmax in HIV1 infected human at 10 mg after 24 hrs presence of 400 mg of Lopinavir and 100 mg of itonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID86696Tested in vitro for anticancer activity against HepG2 cells1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.
AID152632Tested in vitro for anti HIV-1 activity against PBM cells1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.
AID544197Clearance in human at 20 mg administered under fasting condition2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID543741Time prior to start absorption at second absorption site in HIV1 infected human at 20 mg after 24 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID8449Tested in vitro for anticancer activity against 9L cells; Not determined1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.
AID543506Drug level in HIV1 infected human plasma at 10 mg after 24 hrs presence of 400 mg of Lopinavir and 100 mg of itonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID543514Drug level in HIV1 infected human plasma at 5 mg qd for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID202327Tested in vitro for anticancer activity against SK-MES-1 cells1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.
AID544202AUC (0 to infinity) in human at 20 mg administered under fasting condition in presence of 300 mg of ritonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID544203Cmax in human at 20 mg administered under fasting condition in presence of 300 mg of ritonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID544192Terminal half life in human at 20 mg administered under fasting condition presence of 300 mg of ritonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID86885Tested for cytotoxicity in human hepatoma cell (2.2.15); not cytotoxic at the highest concentration tested (70 uM)1998Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1
Bis-S-acyl-2-thioethyl (SATE)-bearing monophosphate prodrug of beta-L-FD4C as potent anti-HBV agent.
AID37900Tested for cytotoxicity in murine melanoma (B16); not cytotoxic at the highest concentration tested (70 uM)1998Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1
Bis-S-acyl-2-thioethyl (SATE)-bearing monophosphate prodrug of beta-L-FD4C as potent anti-HBV agent.
AID544209Peripheral volume of distribution with respect to the bioavailability in human at 20 mg administered under fasting condition2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID543511AUC (0 to 24 hrs) in HIV1 infected human at 5 mg qd for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID543503AUC (0 to 24 hrs) in HIV1 infected human at 10 mg after 24 hrs presence of 400 mg of Lopinavir and 100 mg of itonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID104418In vitro inhibitory activity against growth of HIV infected MT-2/IIIB cell line1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Synthesis and comparative evaluation of two antiviral agents: beta-L-Fd4C and beta-D-Fd4C.
AID152625Tested in vitro for anti HIV-1 activity against PBM cells1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.
AID46361In vitro concentration required to decrease 50% of mitochondrial DNA content in CEM cells1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human
AID543516AUC (0 to 24 hrs) in HIV1 infected human at 10 mg qd for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID543525Half life in HIV1 infected human at 20 mg administered once every 48 hrs for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID83235In vitro inhibitory activity against proliferation of HIV viral cell1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Synthesis and comparative evaluation of two antiviral agents: beta-L-Fd4C and beta-D-Fd4C.
AID155299Cytotoxicity was determined in PBM cells, relative to RVT2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions.
AID543519Drug level in HIV1 infected human plasma at 10 mg qd for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID47449Tested in vitro for anticancer activity against CEM cells1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.
AID544199Half life in human at 20 mg administered under fasting condition2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID216188Tested in vitro for cytotoxicity against Vero cells1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.
AID543515Half life in HIV1 infected human at 5 mg qd for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID104417Compound was tested for anti-HIV activity in MT-2/ IIIB cells and the ratio of the drug concentration (ID50) required to inhibit cell growth was reported.1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Synthesis and biological evaluation of a series of 2'-fluorinated-2',3'-dideoxy-2',3'-didehydro-(L)-nucleosides.
AID43044Tested for cytotoxicity in murine colon cancer (C26); not cytotoxic at the highest concentration tested (70 uM)1998Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1
Bis-S-acyl-2-thioethyl (SATE)-bearing monophosphate prodrug of beta-L-FD4C as potent anti-HBV agent.
AID156334Tested in vitro for anticancer activity against PC-3 cells1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.
AID543513Tmax in HIV1 infected human at 5 mg qd for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID3034Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human
AID544240Tmax in human at 20 mg administered under fasting condition in presence of 300 mg of ritonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID543524Drug level in HIV1 infected human plasma at 20 mg administered once every 48 hrs for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID544198Tmax in human at 20 mg administered under fasting condition2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID543698Terminal half life in HIV1 infected human at 20 mg administered once every 48 hrs for 21 days in presence of 400 mg of Lopinavir and 100 mg of itonavir administered once every 12 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID155105The anti-HIV-1 activity was assayed in activated human peripheral blood mononuclear (PBM) cells, relative to RVT2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions.
AID53792In vitro inhibitory activity against growth of HIV infected DLD-1 cell line1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Synthesis and comparative evaluation of two antiviral agents: beta-L-Fd4C and beta-D-Fd4C.
AID201986Tested in vitro for anticancer activity against SK-MEL-28 cells1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.
AID543492Cmax in HIV1 infected human at 5 mg after 24 hrs presence of 400 mg of Lopinavir and 100 mg of itonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
AID544205Apparent oral clearance in human at 20 mg administered under fasting condition presence of 300 mg of ritonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID544239Clearance in human at 20 mg administered under fasting condition in presence of 300 mg of ritonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID24722Estimated half-life at 20 degree C in 0.05 M pH 2 NaH2PO4 buffer2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions.
AID544195AUC (0 to infinity) in human at 20 mg administered under fasting condition2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID544208Distributional clearance with respect to the bioavailability in human at 20 mg administered under fasting condition presence of 300 mg of ritonavir2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID544249Absorption rate constant at second absorption site in human at 20 mg administered under fasting condition2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
AID46571In vitro inhibitory activity against growth of HIV infected CEM cells combined with murine CTLL-2T lymphoblast cell line1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Synthesis and comparative evaluation of two antiviral agents: beta-L-Fd4C and beta-D-Fd4C.
AID544204Apparent oral clearance in human at 20 mg administered under fasting condition2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (55.56)18.2507
2000's4 (44.44)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.22 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (11.11%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thymine
[no description available]		2.0210pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite
flucytosine
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.		2.0210aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone		prodrug
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		210nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
cycloheximide
Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.		2.4120antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
furfuryl alcohol
furfuryl alcohol: structure. furfuryl alcohol : A furan bearing a hydroxymethyl substituent at the 2-position.		2.0210furans;
primary alcohol		Maillard reaction product
stavudine
Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase		2.4220dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		2.4120azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
lamivudine
[no description available]		2.4120monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
emtricitabine
Emtricitabine: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.. emtricitabine : An organofluorine compound that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection.		1.9910monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
2',3'-dideoxycytidinene
2',3'-dideoxycytidinene: 2',3'-unsaturated derivative of 2',3'-dideoxycytidine; potent inhibitor of HTLV-III in vitro; structure given in first source		1.9910
dexelvucitabine
dexelvucitabine: inhibits human hepatitis B virus (HBV) and human immunodeficiency virus (HIV) in vitro		2.420
2',3'-dideoxy-2',3'-didehydro-2'-fluorocytidine
2',3'-dideoxy-2',3'-didehydro-2'-fluorocytidine: has antiviral action against HIV-1; structure given in first source		2.0110
2',3'-dideoxy-beta-5-fluorocytidine
2',3'-dideoxy-beta-5-fluorocytidine: structure in first source		2.420
abacavir
abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.		2.01102,6-diaminopurinesantiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor
guanine
[no description available]		2.02102-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		02.6830
HIV Coinfection
[description not available]		02.0510
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		14.4520